Secukinumab | springermedizin.de

Springer Medizin

nach oben

Reactions Weekly

Erschienen in:

01.12.2023 | Case report

Secukinumab

Drug resistance: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Excerpt

Author Information

An event is serious (based on the ICH definition) when the patient outcome is:

* death
* life-threatening
* hospitalisation
* disability
* congenital anomaly
* other medically important event

…

Anzeige

Chen Y, et al. Transition from secukinumab to adalimumab in COVID-19-induced psoriasis flare-up treatment: A case report. Clinical Case Reports 11: no pagination, No. 10, Oct 2023. Available from: URL: http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)2050-0904

Titel: Secukinumab
Drug resistance: case report
Publikationsdatum: 01.12.2023
Verlag: Springer International Publishing
Erschienen in: Reactions Weekly / Ausgabe 1/2023
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-023-51242-7